VolitionRx Granted Its Third U.S. Patent

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. HOOD
5. SPY
6. CDNS
7. ANT
8. META
9. STX
10. INTC

Go back to VolitionRx Granted Its Third U.S. Patent

Volitionrx Limited (VNRX) Chief Medical Officer to Assume Full-Time Role

January 5, 2016 7:09 AM EST

Volitionrx Limited (NYSE: VNRX) announced that Jason Terrell, MD transitioned to full-time status as Chief Medical Officer and Head of U.S. Operations, effective January 1, 2016. Dr. Terrell has served in a part-time capacity as the Company's Chief Medical Officer and Head of U.S. Operations since March 2013. Dr. Terrell will continue to lead and coordinate VolitionRx's U.S. operations in preparation for initial market entry of the Company's NuQ® blood tests for cancer in the U.S. and worldwide.VolitionRx Limited"The recent results of clinical trials by VolitionRx have been so... More